Volkova, Nataliya

Disease progression in patients with cystic fibrosis treated with ivacaftor: Data from national US and UK registries

Volkova, N., Moy, K., Evans, J., Campbell, D., Tian, S., Simard, C., Higgins, M., Konstan, M. W., Sawicki, G. S., Elbert, A., et al. (2020) · Journal of Cystic Fibrosis

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 258

Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor

Bessonova, L., Volkova, N., Higgins, M., Bengtsson, L., Tian, S., Simard, C., Konstan, M. W., Sawicki, G. S., Sewall, A., Nyangoma, S., et al. (2018) · Thorax

Cystic Fibrosis Research AdvancesInhalation and Respiratory Drug Delivery

Cited by 214

Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study

Bower, J. K., Volkova, N., Ahluwalia, N., Sahota, G., Xuan, F., Chin, A., Weinstock, T. G., Ostrenga, J., & Elbert, A. (2023) · Journal of Cystic Fibrosis

Cystic Fibrosis Research AdvancesPharmacogenetics and Drug Metabolism

Cited by 140